Get the Stockscreener App
4.715
8.35%
-0.435
Aquestive Therapeutics Inc stock is traded at $4.715, with a volume of 2.50M.
It is down -8.35% in the last 24 hours and down -4.65% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
See More
Previous Close:
$5.15
Open:
$5
24h Volume:
2.50M
Relative Volume:
1.95
Market Cap:
$468.96M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-10.48
EPS:
-0.45
Net Cash Flow:
$-24.91M
1W Performance:
-16.61%
1M Performance:
-4.65%
6M Performance:
+34.09%
1Y Performance:
+195.00%
1-Day Range:
$4.62
$5.12
1-Week Range:
$4.62
$5.80
52-Week Range:
$1.52
$6.23
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive Therapeutics (NASDAQ:AQST) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Aquestive Therapeutics: Q3 Earnings Snapshot - mySA
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Aquestive Therapeutics reports Q3 EPS (13c), consensus (13c) - TipRanks
AQSTAquestive Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Aquestive Therapeutics Optimistic Financial and Strategic Outlook - TipRanks
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Aquestive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aquestive Therapeutics Inc (AQST) Q3 2024: Everything You Need T - GuruFocus.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $8.83 Consensus Target Price from Brokerages - MarketBeat
Learn to Evaluate (AQST) using the Charts - Stock Traders Daily
Aquestive Therapeutics (NASDAQ:AQST) Price Target Raised to $13.00 - Defense World
Aquestive Therapeutics (AQST) Set to Announce Quarterly Earnings on Monday - MarketBeat
Leerink raises Aquestive Therapeutics stock PT on 'top-line' study results - Investing.com Canada
Aquestive Therapeutics to Present Subsequent Analysis of - GlobeNewswire
Leerink Partners Raises Aquestive Therapeutics (NASDAQ:AQST) Price Target to $13.00 - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Aquestive Therapeutics’ Breakthrough in Allergy Treatment Study - Yahoo Finance
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American - GlobeNewswire
Institutions profited after Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) market cap rose US$51m last week but individual investors profited the most - Simply Wall St
Aquestive Therapeutics' SWOT analysis: stock poised for growth as Anaphylm nears FDA submission - Investing.com Australia
Aquestive Therapeutics Pushes Retail Sentiment Into ‘Extremely Bullish’ Zone On OAS Drug Trial Success - Barchart
Aquestive Therapeutics' SWOT analysis: stock poised for growth as Anaphylm nears FDA submission By Investing.com - Investing.com South Africa
Aquestive Therapeutics Inc (AQST) Has Recovered 74.67% From Its Low: Is This The Beginning Of A Trend? - Stocks Register
Aquestive Therapeutics Announces Positive Topline Results - GlobeNewswire
Aquestive Therapeutics a new overweight at Piper on oral film products - MSN
Aquestive Therapeutics to Report Third Quarter 2024 - GlobeNewswire
Aquestive Therapeutics updates bylaws, shortens nomination look-back By Investing.com - Investing.com South Africa
Aquestive Therapeutics updates bylaws, shortens nomination look-back - Investing.com India
Investing in Aquestive Therapeutics Inc (AQST) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Financial Snapshot: Analyzing Aquestive Therapeutics Inc (AQST)’s Key Ratio Metrics - The Dwinnex
Top investors say Aquestive Therapeutics Inc (AQST) ticks everything they need - SETE News
Aquestive Therapeutics (NASDAQ:AQST) Given "Market Outperform" Rating at JMP Securities - MarketBeat
In the Green: Aquestive Therapeutics Inc (AQST) Closes at 4.85, Up/Down -2.02 from Previous Day - The Dwinnex
Should investors be concerned about Aquestive Therapeutics Inc (AQST)? - US Post News
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $8.67 Average Price Target from Brokerages - MarketBeat
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Position Trimmed by Renaissance Technologies LLC - MarketBeat
A better buy-in window may exist right now for Aquestive Therapeutics Inc (AQST) - SETE News
Can you now get a good deal on Aquestive Therapeutics Inc’s shares? - US Post News
Aquestive Therapeutics stock target lifted, rating held on product pipeline By Investing.com - Investing.com Canada
aquestiveinvestordayreca.htm - SEC.gov
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate - AOL
Trading Day Review: Aquestive Therapeutics Inc (AQST) Loses Momentum, Closing at 4.72 - The Dwinnex
AQST’s Stock Tango: The Dance of Gains and Losses in 2023 - The InvestChronicle
Aquestive Therapeutics (NASDAQ:AQST) Earns "Market Outperform" Rating from JMP Securities - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Price Target Raised to $10.00 - MarketBeat
146,155 Shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Purchased by Deerfield Management Company L.P. Series C - MarketBeat
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day - GlobeNewswire
Aquestive advances epinephrine treatments, completes study By Investing.com - Investing.com South Africa
Wall Street SWOT: Aquestive Therapeutics stock poised for potential breakthrough - Investing.com
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aquestive Therapeutics Inc Stock (AQST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schobel Alexander Mark | Chief Innovation/Tech Officer |
Mar 08 '24 |
Sale |
5.19 |
25,000 |
129,685 |
1,040,371 |
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):